IP Library Granted Patent US 8,609,668
Granted Patent B2
US 8,609,668 · App. 12/299,532 · Granted Dec 17, 2013

Substituted triazolo[1,5-A]pyrimidines as antiviral agents

Inventors: Andrea Cuconati (Oreland, PA); Timothy M. Block (Doylestown, PA); Xiaodong Xu (Doylestown, PA)
Assignees: Philadelphia Health & Education Corporation; Institute For Hepatitis and Virus Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,609,668
App. No.
12/299,532
Granted
Dec 17, 2013
Kind
B2
Abstract

A pharmaceutical composition comprising an effective amount of a compound of formulas (I-III) and a pharmaceutically acceptable carrier. Methods for treating a hepatitis virus in a patient comprising administering an effective amount of the compound of formulas (I-III) are also presented.

Claims (12)

1. A method for treating a hepatitis B virus in a patient comprising administering an effective amount of a composition to a patient in need thereof comprising:

(a) an effective amount of a compound selected from the group consisting of Formulas I, II, III, and mixtures thereof;

wherein

R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 each independently represent a phenyl or Het, wherein each phenyl or Het is optionally substituted with at least one substitutuent independently selected from the group consisting of alkyl, cycloalkyl, acyl, aryl, halo, OR a , trifluoromethoxy, trifluoromethyl, NO 2 , NR a R b , cyano, CONR a R b , and CO 2 R a ;

X 1 , X 2 , X 3 , X 4 , X 5 , and X 6 are selected from the group consisting of a bond, a saturated alkylenegroup and an unsaturated alkylenegroup;

R a and R b are each independently H, alkyl, cycloalkyl, alkanoyl, alkanoyloxy,or aryl, or R a and R b together with a nitrogen to which they are attached form a Het; and

(b) a pharmaceutically acceptable carrier.

2. A method for treating a hepatitis B virus in a patient in need thereof comprising administering to said patient an effective amount of a compound selected from the group consisting of formula I, II, III, and mixtures thereof that reduce the serum level of hepatitis B surface antigen (HBsAg) in said patient, said formula I, II, and III defined as follows:

wherein

R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 each independently represent a phenyl or Het, wherein each phenyl or Het is optionally substituted with at least one substitutuent independently selected from the group consisting of alkyl, cycloalkyl, acyl, aryl, halo, OR a , trifluoromethoxy, trifluoromethyl, NO 2 , NR a R b , cyano, CONR a R b , and CO 2 R a ;

X 1 , X 2 , X 3 , X 4 , X 5 , and X 6 are selected from the group consisting of a bond a saturated alkylenegroup and an unsaturated alkylenegroup;

R a and R b are each independently H, alkyl, cycloalkyl, alkanoyl, alkanoyloxy, or aryl, or R a and R b together with a nitrogen to which they are attached form a Het.

Assignments (2)
MERGER Recorded Nov 19, 2014
From: PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE
To: DREXEL UNIVERSITY
Reel/Frame 034209/0083 →
CHANGE OF NAME Recorded Nov 18, 2014
From: INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH
To: BARUCH S. BLUMBERG INSTITUTE
Reel/Frame 034282/0687 →
Continuity (2)
Provisional Application 60797581 · May 4, 2006
Related Publication 20090088397A1 · Apr 2, 2009